Since the success of mRNA vaccines, smart money is moving to venture capitalize the tech for all kinds of purposes:
Moderna executives tout the company’s pipeline often—so we’ll be brief here. A cytomegalovirus candidate is the furthest along in the company’s prophylactic vaccine program, while other mid-stage assets include a personalized cancer vaccine and a localized regenerative therapeutic for the heart condition myocardial ischemia.
BioNTech, meanwhile, has dozens of assets in development for a host of common conditions: malaria, tuberculosis and even certain allergies. But where the German biotech is really making a mark is in oncology, where dozens of vaccines and therapeutics are in development. Just one is in phase 2: the Roche-partnered melanoma therapy BNT122. That drug is combined with Merck & Co.’s blockbuster Keytruda to treat metastatic melanoma in a study conducted with Roche’s Genentech.
Several Big Pharma peers have rushed to grab hold of a technology that could have incredible promise in developing therapeutics and vaccines for everything from oncology to lung diseases. Pfizer, for instance, sees mRNA taking a bigger bite out of its pipeline in the years to come after the success of the BioNTech partnership.
Last edited: